Pulmonary Surfactant Market: Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the market growth | Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc

Lung surfactants are administered to prevent and treat infant respiratory distress syndrome (RDS). Each year, RDS affects over 40,000 infants in the U.S. and Canada, which is a serious side effect of premature delivery. The lungs eventually collapse due to poor lung compliance brought on by a functional or quantitative surfactant deficit. Surfactant, a mixture of neutral lipids, neutral phospholipids, and proteins produced by pneumocytes during pregnancy, improves lung compliance and shortness of breath by stabilising alveoli and reducing surface tension.

Get Research Sample PDF with Market Development Insights @ https://www.coherentmarketinsights.com/insight/request-sample/5324

The growth of the global pulmonary surfactant market is being driven by an increase in the prevalence of different lung diseases. For instance, on May 11, 2022, the World Health Organization released a report that stated that asthma is a serious noncommunicable disease (NCD) that affects both children and adults, and that it is the most prevalent chronic disease in children. Asthma symptoms, such as coughing, wheezing, shortness of breath, and chest tightness, are brought on by inflammation and narrowing of the small airways in the lungs. Moreover, according to the same source, asthma is thought to have affected 262 million people worldwide in 2019 and contributed to 455,000 fatalities.

The global pulmonary surfactant market is anticipated to be driven by the potential for pulmonary surfactant (PS) to be strategically used for drug delivery over the respiratory air-liquid interface. For instance, the use of pulmonary surfactant as a drug delivery system is highly promising, according to a report from the National Center for Biotechnology Information, the National Library of Medicine of the United States. Pulmonary surfactant may transport the drug by surfing the air-liquid interface towards the distal Airways, and breathing dynamics may also contribute to drug diffusion and release along with surfactant components.

Impact

The coronavirus, also known as COVID-19, outbreak began in Wuhan, China in 2019 and has since spread to every continent, having an impact on a number of global industries. Since 2020, governments around the world have imposed lockdowns to stop the spread of the coronavirus, disrupting the economies of nations like India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others.

During COVID-19, the use of pulmonary surfactant in the management of acute respiratory distress syndrome was crucial. For instance, Frontiers Media, a publisher of peer-reviewed open access scientific journals, released a report in June 2021 that claimed SARS-CoV-2 enters the body through the lungs’ ACE-2 (angiotensin converting enzyme) receptor and that (AT) alveolar type II cells (play a crucial role as part of the immune system).

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5324

The pulmonary surfactant is produced in AT II cells. Newborn respiratory distress syndrome and viral infections are known to lower pulmonary surfactant levels in the lungs. Lack of pulmonary surfactant is the primary cause of NRDS. The cornerstone of NRDS treatment worldwide is PS therapy.

The global market for pulmonary surfactants has grown as a result of the coronavirus (COVID-19) pandemic during the anticipated period.

Key Developments

The global market for pulmonary surfactants is expanding as a result of key players placing more emphasis on research and development for respiratory diseases. For instance, on February 1, 2022, Windtree Therapeutics, Inc., a U.S.-based company focused on advancing a number of late-stage interventions for acute cardiovascular and pulmonary disorders, announced that enrollment in its Phase 2 study of lucinactant—a liquid medication used to treat infant respiratory distress syndrome—for patients with COVID-19-associated lung injury and ac (ARDS). In order to assess the safety and tolerability of lucinactant administered as a liquid through the endotracheal tube in patients who are mechanically ventilated as a result of COVID-19 associated acute lung injury, the Phase 2 trial is a multicenter, single-treatment study involving 20 patients.

The development of the global pulmonary surfactant market is driven by growing consensus among the major market players. For instance, to advance the treatment of respiratory distress syndrome in premature infants in China, Aerogen Pharma, a pharmaceutical company, entered an agreement with Nuance Pharma, a clinical-stage biopharmaceutical company. According to the agreement, Nuance will have the sole right to create and market AeroFact in Greater China. AeroFact is a novel therapy that combines a well-known pulmonary surfactant drug with a unique vibrating mesh nebulizer aerosolization technology (Mainland China, Taiwan, Hong Kong and Macau). For the hundreds of thousands of premature babies around the world whose healthy development is threatened by RDS, the conventional invasively-delivered lung surfactant improved clinical outcomes (Respiratory Distress Syndrome).

Key Takeaways

Due to increased research and development efforts to bring about advancements in the pulmonary surfactant market, the global pulmonary surfactant market is anticipated to experience a CAGR of 4.50% during the forecast period.

Over the course of the forecast period, the market for animal-derived surfactants is anticipated to hold a dominant position. This is a result of animal-derived surfactants becoming more popular due to their lower mortality and complication rates. For instance, the National Center for Biotechnology Information, which is part of the National Library of Medicine in the United States, conducted a study in June 2020 and reported that the patients treated with endobronchial poractant alfa improved in the PaO2/FiO2 ratio (used to assess the severity of lung injury in patients receiving mechanical ventilation) and radiological data without any issues throughout the procedure.

Direct Purchase This Report with Huge Discount ( Up To 25% Off) @ https://www.coherentmarketinsights.com/insight/buy-now/5324

Poractant alfa is anticipated to hold a monopolistic position in the market during the forecast period among Drug type. because there are more advantages and fewer complications. As an illustration, on January 9, 2022, the open access, international, peer-reviewed International Journal of Contemporary Pediatrics published a report of a study on the comparison of natural surfactant poractant alfa and bovine lipid extract for the treatment of respiratory distress syndrome in preterm neonates. When it comes to the need to decrease the number of mechanical ventilators, CUROSURF (poractant alfa) is 6.67% more effective than NEOSURF (bovine lipid extract). Use of CUROSURF was linked to shorter oxygenation times, shorter hospital stays, and lower mean FiO2 needs (The fraction of inspired oxygen). CUROSURF required fewer repeat doses of surfactant than NEOSURF.

Due to better drug reimbursement and pricing in hospital pharmacies as a result of the 340B pricing programme, the hospital pharmacies segment is anticipated to hold a dominant position among distribution channels over the forecast period.

Reddot Biotech, Boehinger Ingelheim, Nanjing Norris Pharm Technology, AbbVie Inc., Biomatik, Chiesi Farmaceutici, Tekzima (Noargen), ONY Biotech Inc., Windtree Therapeutics, Inc., Lyomark Pharma, Aviva Systems Biology Corporation, and Abbott are important market participants in the pulmonary surfactant market.

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
   • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Type
     • Market Snapshot, By Drug Type
     • Market Snapshot, By Indications
     • Market Snapshot, By Route of Administration
     • Market Snapshot, By Distribution Channel
     • Market Snapshot, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Impact Analysis
   • Market Trends
   • Key Developments
   • Regulatory Scenario
   • Industry Trend
   • New Product Approvals/Launch
   • Merger and Acquisitions
   • PEST Analysis
4. Global Pulmonary Surfactant Market COVID-19 Impact Analysis
   • Overall Impact
   • COVID-19 Impact on the market
5. Global Pulmonary Surfactant Market, By Type, 2017 – 2030, (US$ Million)
   • Overview
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Synthetic Pulmonary Surfactant
     •  Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Animal Derived Surfactant
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
6. Global Pulmonary Surfactant Market, By Drug Type, 2017 – 2030, (US$ Million)
   • Overview
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Poractant alfa
     •  Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Lucinactant
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Calfactant
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global Pulmonary Surfactant Market, By Indications, 2017 – 2030, (US$ Million)
   • Overview
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Respiratory Distress Syndrome (RDS)
     •  Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Respiratory Infections
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Obstructive lung Diseases
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
8. Global Pulmonary Surfactant Market, By Route of Administration, 2017 – 2030, (US$ Million)
   • Overview
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Intratracheal
     •  Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Injectable
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
9. Global Pulmonary Surfactant Market, By Distribution Channel, 2017 – 2030, (US$ Million)
   • Overview
     • Market Share Analysis, 2022 and 2030 (%)
     • Y-o-Y Growth Analysis, 2017 – 2030
     • Segment Trends
   • Hospital Pharmacies
     •  Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Retail Pharmacies
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
   • Online Pharmacies
     • Overview
     • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)

View Press Release: https://www.coherentmarketinsights.com/press-release/pulmonary-surfactant-market-4621